Oxford Biomedia's debut flops
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Stock market jitters hammered another two new issues yesterday when Oxford Biomedica shares opened at less than half their placing price and it emerged that Fountain Forestry was cutting by 50 per cent the amount being raised from its own Alternative Investment Market flotation.
Oxford, a biotechnology group backed by Oxford University, saw its shares start dealings on AIM at just 42.5p yesterday morning, some 52 per cent below the 88p at which the shares were priced in October. They ended slightly up at 47.5p.
Sentiment took a dive earlier this week when it was revealed that the two main underwriters, Stockton Trading, a Bahamian-registered company, and Kaj Kjellquist, a private Swedish investor, had withdrawn their combined pounds 5m commitment to underwrite the pounds 6.15m then being raised. The move forced the company to delay first dealings until yesterday and reduce the amount being raised to pounds 5m, which Oxford said was its minimum working capital requirement, although it had originally sought up to pounds 11m.
Percy Lomax of sponsoring brokers Teather & Greenwood said the company was reserving its right to take legal action against the underwriters.
The flop is the latest in a list of disappointing biotechnology flotations. Earlier this year, Cambrio abandoned plans to float, and Xenova has been forced to cut the amount being raised by pounds 2.4m to pounds 22.6m.
The news came as Fountain Forestry said its placing would raise pounds 2.25m, half the original target of pounds 4.5m. Yeoman, a navigation group that also postponed its AIM float this week, saw its shares end 4.5p down on its 175p placing price.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments